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Summary 
In this perspective, we identify emerging frontiers 
in clinical and basic research of melanocyte biology and its 
associated biomedical disciplines. We describe challenges 
and opportunities in clinical and basic research of normal 
and diseased melanocytes that impact current approaches 
to research in melanoma and the dermatological sciences. 
We focus on four themes: (1) clinical melanoma research, 
(2) basic melanoma research, (3) clinical dermatology, and 
(4) basic pigment cell research, with the goal of outlining 
current highlights, challenges, and frontiers associated with 
pigmentation and melanocyte biology. 
Significance 
This document encapsulates important advances 
in melanocyte and melanoma research including emerging 
frontiers in melanoma immunotherapy, medical and 
surgical oncology, dermatology, vitiligo, albinism, genomics 
and systems biology, epidemiology, pigment biophysics and 
chemistry, and evolution. 
1. Introduction 
Variability and dysfunction in pigment-producing 
melanocytes lead to considerable consequences for both 
human and animal physiology. We describe emerging 
frontiers in clinical and basic research of normal and 
diseased melanocytes that impact current approaches to 
research in melanoma and the dermatological sciences. We 
focus on four themes, organized in corresponding sections: 
(1) clinical melanoma research, (2) basic melanoma 
research, (3) clinical dermatology, and (4) basic pigment cell 
research, with the goal of outlining current highlights, 
challenges, and frontiers associated with pigmentation and 
melanocyte biology. 
The council of the Pan American Society for 
Pigment Cell Research has summoned a comprehensive 
assessment of the current state of progress in melanoma 
research and dermatological sciences. Intensive discussions 
among members of the International Federation of Pigment 
Cell Societies (IFPCS), the International Pigment Cell 
Conference (IPCC) 1, the Society of Melanoma Research 
(SMR) 1, the Skin of Color Society (SOCS), and the Melanoma 
Prevention Working Group (MPWG) nucleated this 
perspective and culminated in the current status, 
challenges, and opportunities of respective thematic 
research areas (Box et al., 2018). The scope of this 
perspective was to highlight emerging trends in the four 
thematic areas, rather than aiming for exhaustive 
completeness, with a few citations limited to those 
appearing in the past 12 months. 
In the field of clinical melanoma, mechanistic 
understanding based on genomic and immunological data 
has led to extraordinary recent progress in diagnosing and 
treating melanoma tumors. In clinical dermatology, loss of 
normal pigmentation is mediated by inflammatory, 
immunological, and genetic determinants. Vitiligo 
management innovates by reversing skin disease through 
suppression of autoimmune inflammation and promoting 
melanocyte regeneration. Progress in management of 
albinism includes providing precise molecular definition of 
underlying genetic mutations, limiting ultraviolet (UV) light 
exposure by physical barriers, and in the future support by 
pharmacologic and genetic intervention. In melasma and 
hyperpigmentation areas, the frontlines are molecular 
understanding of pathogenesis and systematic evaluation 
of which combinations of topical, oral, and procedural 
therapies are most effective in treating postinflammatory 
hyperpigmentation. In basic melanoma and dermatology 
research, current frontiers include understanding of 
genomic profiles, signaling pathways, and biophysics of 
melanins to arrive at comprehensive insights into 
developmental and biomedical properties of pigment cells. 
2. Results and Discussion 
2.1 SECTION 1—CLINICAL MELANOMA 
RESEARCH 
2.1.1 State of the art of immunotherapy of 
malignant melanoma 
Immunotherapy has moved to center stage in 
melanoma treatment with the recent success of trials 
involving blockade of immune checkpoints (Weber et al., 
2017). The cytotoxic T lymphocyte–associated antigen 4 
(CTLA4, CD152), and the combination of programmed 
death 1 (PD-1, PDCD1, CD279) and programmed death 1 
ligand (PD-L1, PDCD1L1, CD274) comprise immune 
checkpoints and negative regulators of T cell immune 
function. The roles of CTLA4 and PD-1 in inhibiting immune 
responses, including antitumor responses, are largely 
distinct. CTLA4 can regulate T cell proliferation early in an 
immune response, primarily in lymph nodes, whereas PD-1 
suppresses T cells later in an immune response, primarily in 
peripheral tissues. Inhibition of these targets has provided 
successful modes of intervention, leads to increased 
activation of the immune system, and has led to new 
immunotherapies for melanoma and other cancers. 
Ipilimumab, an inhibitor of CTLA4, is approved for the 
treatment of advanced or unresectable melanoma. 
Nivolumab and pembrolizumab, both PD-1 inhibitors, are 
approved to treat patients with advanced or metastatic 
melanoma and patients with metastatic, refractory non-
small cell lung cancer. In addition, the combination of 
ipilimumab and nivolumab has been approved in patients 
without B-Raf proto-oncogene, serine/threonine kinase 
(BRAF) activating mutations and metastatic or unresectable 
melanoma. Checkpoint regulators on T cells play vital roles 
in limiting adaptive immune responses and preventing 
autoimmune and auto-inflammatory reactivity in the 
normal host (Najjar et al., 2017). In cancer patients, PD-1 
expression can be very high on T cells in the tumor 
microenvironment, and PD-L1, its primary ligand, is variably 
expressed on tumor cells and antigen-presenting cells 
within tumors, providing a potent inhibitory influence 
within the tumor microenvironment. While PD-L1 
expression on tumors is often regarded as a negative 
prognostic factor, it can be associated with a positive 
outcome for treatment with PD-1/PD-L1 blocking 
antibodies, and has been used to select patients for this 
therapy. Therapy regimens with immune checkpoint 
blocking antibodies are characterized by responses of long 
duration, while a minority of patients displays atypical 
responses. In such cases, progression may precede tumor 
shrinkage, and a pattern of autoimmune side effects is 
associated with this class of drugs. Even though excellent 
efficacy and some complete remissions have been seen in a 
limited number of melanoma patients, some of whom may 
be regarded as cured of cancer, many malignancies do not 
show responses of long duration with these agents. 
Predicting tumor responses to immune checkpoint 
blockade remains a major challenge and an active field of 
research fueled by systems biology data. 
2.1.2 Targeted therapy, combination therapy and 
treatment resistance 
Inhibition of the mitogen-activated protein kinase 
(MAPK) pathway using BRAF kinase inhibitors or MAP2K 
(MEK1/2) inhibitors as single agents improves survival of 
patients with BRAF(V600E)–mutant metastatic melanoma 
compared with standard chemotherapy. Although BRAF-
activated melanomas have initially been the most 
responsive melanoma subset due to targeted therapies, 
patients ultimately develop resistance. Accordingly, there is 
now rapid progress in combinatorial therapeutic 
approaches, especially ones taking advantage of engaging 
the immune system to fight cancer cells. Concurrent BRAF 
and MEK inhibition improved clinical outcomes further over 
single-agent BRAF inhibitors, with decreased toxicities 
related to paradoxical activation of the MAPK pathway in 
BRAF wild-type cells (Dummer et al., 2018). More than 95% 
of patients experienced tumor reduction when treated with 
MEK inhibitors dabrafenib and trametinib in combination. 
Although 50% of patients showed disease progression after 
12 months, a fraction of patients experienced long-term 
progression-free survival. The future selection of patients 
for combined BRAF and MEK inhibition, and the rational 
design of clinical trials for those who fail this combination 
will be assisted by analysis of the clinical, genomic, 
biochemical, and pathological features of those 
experiencing long-term benefit versus those who progress. 
Early responses to BRAF inhibitors are a major determinant 
for long term beneficial outcome. The faster the response, 
the more long-lasting and deep the remission tends to be. 
Melanoma phenotypic plasticity describes how tumors 
adapt and evolve to selective pressure of MAPK blockade. 
Melanoma cells respond to the selective pressure of MAPK 
inhibition through diverse mechanisms of adaptations 
including genomic, transcriptomic, and epigenomic 
alterations. Cellular models established to quantify 
responses to clinical dosage of MAPK inhibitors have 
provided system-level insight into aberrant reactivation of 
signaling cascades in response to drug resistance. 
Downregulation of intracellular inhibitory dual-specific 
phosphatases (DUSPs) eliminates off-switches of kinases 
and reengages downstream MAPK effectors. Increase in 
receptor tyrosine kinase (RTK) ligands, either through 
autocrine production from tumor cells, paracrine secretion 
from stroma, or systemic production, promotes resistance 
to kinase inhibitors. By remodeling of cell surface RTK 
receptors, including insulin like growth factor 1 receptor 
(IGF1R), receptor tyrosine kinase MET proto-oncogene, or 
platelet derived growth factor receptors (PDGFRA/B), an 
adaptation-associated signaling network promotes 
intracellular signaling reactivating MAPK or AKT targets. In 
addition, cell adhesion signaling cooperates with RTK 
signaling. There are several pharmacological strategies to 
overcome this resistance. Ceritinib, an anaplastic 
lymphoma kinase (ALK) receptor tyrosine kinase inhibitor 
approved for use in lung cancer, enhances efficacy of 
trametinib in melanoma cells through non-ALK 
mechanisms. Combined inhibition of BRAF and cell cycle via 
cyclin dependent kinase 4/6 (CDK4/6) has the ability to 
block aberrant cell proliferation. Determining patient-
specific therapeutic responses will have a major impact on 
defining an optimal fit for a growing spectrum of targeted 
therapeutic treatments and schedules. 
2.1.3 Melanoma heterogeneity in progression and 
therapy resistance 
Identification of precision medicine profiles and 
stratification of skin cutaneous, uveal, mucosal, and acral 
melanoma are a defined goal of the melanoma research 
community (Filipp, 2017; Hayward et al., 2017). In 
melanoma patients, tumor cells activate pathways common 
to proliferating fibroblasts, endothelial cells, or even 
inflammatory and immune cells. Tumor cell surface 
receptors and tumor-secreted proteins are associated with 
mitogenic and proliferative signaling, migration, invasion, 
and antiapoptosis. In addition, there is a group of molecules 
that is not associated with the phenotype of differentiated 
melanocytes in the skin or surrounding fibroblasts or 
stroma but that represents re-expressed developmental 
genes. Several developmental pathway genes, such as 
those associated with neurotrophin signaling, noncanonical 
WNT, or NOTCH signaling, are commonly expressed by 
melanocyte precursors, stem cells of the dermis, and by 
melanoma cells. However, they are absent in epidermal 
melanocytes. In the future, systems biology approaches 
including large-scale omics platforms or computational 
models will provide mechanistic insight into melanoma 
heterogeneity and therapy resistance (Krepler et al., 2017; 
Zecena et al., 2018). 
2.1.4 Melanoma prevention and epidemiology 
Melanoma is a cancer with globally increasing 
rates. Regions most affected are those predominantly 
populated by individuals of European ancestry and lighter 
pigmentation. Across all populations, there are differences 
in melanoma incidence and mortality by gender and age. In 
general, melanoma incidence correlates with cumulative 
UV exposure and is therefore a function of age. However, 
while there is a greater incidence in older males than 
females of the same age group, such a trend appears to be 
reversed earlier in life, pointing to genetic–epidemiological 
associations. Across the continents, the highest incidence is 
found in Australia (up to 40 per 100,000) followed by 
Northern America and Europe (>10 per 100,000). Rare cases 
(<0.5 per 100,000) are observed in Asia and Africa. Efforts 
comprise primary prevention—above all—in children and 
adolescents aimed at reducing harmful UV exposure to 
prevent the initiation of carcinogenesis. Secondary 
prevention is focused on screening and early detection of 
disease or precursor lesions. Lastly, tertiary prevention is 
aimed at recurring or second primary incidences of disease 
in combination with targeted chemopreventive efforts in 
high-risk populations. The multidisciplinary group 
dedicated to melanoma prevention includes patient 
advocates, melanoma foundation leaders, basic scientists, 
epidemiologists, bioinformaticians, social psychologists, 
and clinician-investigators from dermatology, 
dermatopathology, medical oncology, surgical oncology, 
and radiation oncology. Going forward, collaborative 
efforts are focused on incorporating training and education, 
smartphone app-based image acquisition, big data-driven 
technologies, and machine-learning into melanoma 
prevention and early detection efforts. 
2.2 SECTION 2—BASIC MELANOMA RESEARCH 
2.2.1 Oncogenic signaling in melanoma 
Frontiers in basic melanoma research cover a 
spectrum from molecular and cellular pathogenesis of 
melanoma initiation to malignant disease progression. 
Topics include skin-UV interactions, melanocyte 
carcinogenesis, their resistance to DNA damage and 
carcinogens, molecular regulators of malignant 
transformation, mechanisms of tumor progression and 
metastasis, and determinants of sensitivity to treatment 
regimen. Based on genomic signatures, it is established that 
UV damage drives genomic instability, mutagenesis, and 
carcinogenesis. UV damage in particular fuels the malignant 
transformation of melanocytes into melanoma. Therefore, 
limiting DNA damage is important to prevent melanoma 
development and progression. Melanin offers significant 
protection against DNA damage in the basal layer of the skin 
and shields against solar UV radiation-induced DNA 
damage. Photo-protection by sunscreens can be assessed 
by measuring UV-induced gene expression changes in the 
skin. The UV response pathways of melanocortin 1 receptor 
(MC1R) and endothelin 1 (EDN1) signaling demonstrated 
convergence in melanocyte DNA repair. Specifically, EDN1 
could compensate for loss of the MC1R signaling axis by 
reducing generation of free radicals and photoproducts as 
well as enhancing DNA repair in vitro in human 
melanocytes. The MC1R and cyclic AMP signaling axis 
regulates nucleotide excision repair and accelerated 
clearance of UV damage by cyclic AMP-activated protein 
kinase A (PRKACA) dependent phosphorylation of ATR 
kinase and scaffolding by anchoring proteins. Moreover, 
increased repair by cAMP signaling also extended to 
platinum-induced DNA damage and possibly to interstrand 
cross-linking damage. 
For the topics relating to melanoma progression 
and treatment, improvement of therapy response took 
center stage. In light of immunotherapy having emerged as 
a frontline strategy for patients with melanoma, many 
investigators are actively engaged in determining how 
melanoma cells position themselves to induce and/or 
maintain immune checkpoint blockade. For example, in the 
BRAF(V600E) animal model, response to immune 
checkpoint blockade did not correlate with mutational 
burden or neoantigen load but rather with clonality of 
tumors. Immunotherapy responders tended to have fewer 
distinct tumor clones than nonresponders. Furthermore, 
circulating tumor DNA can be a useful biomarker for 
monitoring treatment responses, for defining clonal 
burden, and to predict which drug combinations best serve 
the patient for minimal side effects but maximal efficacy. In 
other work, estrogen analogues that signal through an 
estrogen-sensing G protein coupled receptor found on 
melanocytes and melanoma cells reduced the ability of cells 
to induce immune checkpoint blockade by downregulating 
major histocompatibility complex, class I components (HLA) 
expression while at the same time increasing tumor antigen 
expression. Moreover, the intestinal microbiome influences 
sensitivity to melanoma immune checkpoint inhibition 
(Gopalakrishnan et al., 2018; Matson et al., 2018; Routy et 
al., 2018). Ongoing research on deregulated metabolism, 
compromised immune homeostasis, composition of gut 
microbiome, and tumor immune infiltrates indicates a role 
of gut health in the response to immune checkpoint 
inhibitors. 
Transcription factors and epigenetic rewiring play 
a pivotal role in melanoma progression and therapy 
resistance. Histone methyltransferases and demethylases 
cooperate with members of the transcriptional machinery 
to modulate oncogenic gene expression. Transcriptional 
and epigenomic master regulators include components of 
the polycomb repressive complex and members of the 
jumonji family, which are dysregulated in melanoma 
patients, and engage in crosstalk between tumor 
metabolism and chromatin remodeling. Vitamin D 
metabolites participate in differentiation of keratinocytes, 
can control melanocyte homeostasis, and influence 
melanoma progression. Expression of cytochrome P450 
family member 26 (CYP26B1) and the nuclear vitamin D 
receptor (VDR) involved in vitamin D signaling is 
dysregulated during melanomagenesis. In contrast, 
expression of nuclear retinoid X receptor alpha (RXRA) in 
keratinocytes in the tumor microenvironment is frequently 
lost during melanoma progression. Expression of EDN1, a 
direct target of nuclear receptor signaling, is enhanced 
during UVB-induced melanomagenesis. RXRA in 
combination with activated CDK4 and oncogenic NRAS 
proto-oncogene induces spontaneous and acute UVB-
induced melanomagenesis. The pathway of G protein 
subunit Gnaq/Gna11 is frequently altered in UV-induced 
melanomas in transgenic hepatocyte growth factor (Hgf) 
overexpression mouse models. Interestingly, early UV 
exposure triggers Gnaq/Gna11 mutations in the 
Braf(V600E) mouse model of melanoma. 
Salt-inducible kinase (SIK) inhibition induces an 
anti-inflammatory phenotype used to stimulate eumelanin 
synthesis to protect against sunburn and photoproduct 
formation. Pheomelanin synthesis could be a contributing 
factor for melanoma progression as in the case of 
amelanotic melanomas. Highlighting melanoma 
immunotherapy for overcoming the immune checkpoint 
blockade, it is recognized that parental neoantigen-devoid 
melanoma cell lines could serve as model of 
immunotherapy resistance, wherein overcoming 
neoantigen deficiency may protect against tumor growths. 
In turn, this might point to the importance of melanocytic 
antigens. Interestingly, Vdr knockout mouse models are 
opiate-seeking. The latter phenotype could be rescued by 
vitamin D supplementation, suggesting a connection 
between UV, vitamin D metabolism, and opiate signaling. 
 
2.2.2 Animal models 
Animal models continue to contribute critically 
important insights into pigment cell and melanoma biology 
(Aktary et al., 2018). Classical genetic approaches in a 
variety of species, including mice and zebrafish, have 
resulted in the identification of an extraordinary number of 
genes and alleles that have strong effects on pigmentation 
phenotypes. Use of pigment cell-specific promoters to drive 
transgenes, including relevant genes, reporters, or genetic 
engineering tools like Cre/CreERT2 recombinase has 
resulted in the generation of widely utilized strains that 
enable a variety of melanoma models and pigment cell 
alterations. Braf(V600E), Nras(Q61K), and cyclin-dependent 
kinase inhibitor Cdkn2a-/- murine models have delivered 
insights into growth-arrested melanocytic nevus 
development and release from senescence, and 
requirements for melanoma initiation. DNA damage, the 
tumor protein TP53, and the cell cycle regulators CDKN2A 
and/or RB1 mediate tumor suppressor-induced escape 
from senescence. Neither CDKN2A nor TP53 is required for 
BRAF-induced growth arrest, but aberrations in those 
components facilitate melanoma progression. The 
complete tumor phenotype requires MAPK and 
mechanistic target of rapamycin kinase (MTOR complex 1 
and 2) activation. MTORC1 perturbation and loss of 
serine/threonine kinase 11 (STK11, LKB1) abrogate BRAF 
induced growth arrest. In addition, DNA methyltransferase 
(Dnmt) and glutamate metabotropic receptor 1 (Grm1) 
melanoma models have been developed, which provide a 
unique focus on noncanonical mitogen activated protein 
kinase pathways, G-protein activation independent of 
Braf/Nras genotypes, epigenetics, and metabolic signaling 
in malignant melanoma. Importantly, these two last 
melanoma models conserve characteristics of melanocytic 
origin. Loss of Dnmts suppressed melanoma in a 
Braf(V600E)/Pten-/- mouse model and enhanced tumor 
latency by reducing AKT phosphorylation. Along the same 
line, loss of transcription factor POU class 3 homeobox 2 
(Brn2) induces tumor initiation in a Braf(V600E)/Pten+/- 
context. Lymphangiogenesis is important in the early stages 
of melanoma invasion and metastasis. Using mouse 
models, tumor cell expression of vascular endothelial 
growth factors (VEGFC/D) promoted lymph vessel 
formation, which fuels metastasis. The heparin binding 
factor midkine (MDK), which signals through integrins as a 
prolymphangiogenic factor, is actively secreted by 
melanoma cells. MDK accumulates at sites of future 
metastasis, establishes new lymph vessel formation, and 
primes the area for arrival of melanoma cells through 
transactivation of vascular endothelial growth factor 
receptor (KDR, VEGFR) expression through MTOR signaling 
and ras homolog family member small GTPases (RAC1 and 
RHOA). In human patients, MDK disrupts the structure of 
the subcapsular sinus of the lymph node, which is relevant 
for blocking tumor cell invasion into the node. Further, 
injection of human induced pluripotent stem cells into 
mouse embryos allows the formation of chimeric animals, 
stimulating studies to understand the human specificities of 
melanomagenesis. These approaches continue to be 
refined and utilized to study important questions in 
pigment cell and melanoma biology. The recent emergence 
of CRISPR/Cas9-based genetic engineering approaches has 
changed the approach to and design of new animal models. 
These tools are being adapted by a large number of 
laboratories, and enable somatic genetic editing in both in 
vitro and in vivo screens with efficiencies that have not been 
possible previously. 
2.3 SECTION 3—CLINICAL DERMATOLOGY 
2.3.1 Clinical research advances on albinism 
Alterations of pigment cells lead to disease 
pathologies that are typically compatible with life, with the 
exception of malignancies and life-threatening forms of 
Hermansky-Pudlak syndrome and Chediak-Higashi 
syndrome. Significantly, however, skin conditions may 
result in psychosocial comorbidities. Albinism is a rare 
genetically inherited condition affecting approximately one 
in twenty thousand people in most world populations. 
Nevertheless, albinism is much more common in sub-
Saharan Africa. People with albinism experience visual 
deficits, hypopigmentation, and sun-sensitivity. In less 
advanced societies, people with albinism may not have 
access to healthcare specialists, sunscreen, or protective 
clothes. Patients are prone to sunburns and UV-dependent 
skin cancers, particularly in regions with a high UV index. If 
not removed in a timely manner, these skin cancers can 
eventually metastasize and cause premature death, often 
before the age of 40. Sadly, patients with albinism in Africa 
face a humanitarian crisis. This crisis stems from a lack of 
access to resources and an alarming increase in ritual 
assassinations of people with albinism (Franklin et al., 
2018). The united pigment cell community stands in 
solidarity and supports patients suffering from albinism, 
leaving a unique footprint in the field of pigment cell 
biology. 
 
 
2.3.2 Progress in clinical and basic research of the 
autoimmune disease vitiligo 
Vitiligo is an acquired chronic depigmenting 
disorder of the skin, with an estimated prevalence of 0.5% 
of the general population. Genetic predisposition and 
environmental triggers likely engage multiple aspects of 
pigment cell biology, including altered immune and 
inflammatory responses, cell death pathways, metabolic 
abnormalities, and impaired cell renewal. In the vast 
majority of cases, vitiligo has an autoimmune basis and is 
often associated with other autoimmune diseases. Immune 
cell infiltrates are frequently found in the perilesional 
margins in actively depigmenting skin. Recent progress in 
the understanding of immune pathomechanisms opens 
avenues for innovative diagnosis and treatment strategies. 
Identifying biomarkers to assess disease activity 
or stability of lesions will be important in the clinical 
management of vitiligo, understanding of disease 
pathogenesis, and in the design of clinical trials. Besides 
measuring levels of chemokines in serum, suction blister 
fluid from lesional skin can serve as an alternative source. 
Cytokine levels in blister fluid appear to be sensitive and 
specific for defining active versus stable disease and 
treatment response. Furthermore, blister fluid allowed 
quantitative phenotyping of melanocytes and their 
lineages, providing insights into vitiligo pathogenesis and 
repigmentation. Phototherapy remains a mainstay 
treatment for targeted vitiligo lesions with less than 10% of 
the body surface affected. The combination of topical 
steroids such as fluticasone propionate along with 
narrowband UVB is safe and provides superior 
repigmentation to narrowband UVB alone. For targeted 
lesions, laser treatment can be particularly effective for 
repigmenting vitiligo. This era has begun to see an advent 
of targeted, molecular therapies for vitiligo. Autoimmunity 
in vitiligo appears to be driven primarily by T cell-derived 
interferon-gamma (IFNG) and its target chemokines, CXCL9 
and CXCL10. Clinical trials in targeting this cytokine pathway 
using the Janus kinase (JAK) inhibitor, ruxolitinib, have 
already been initiated. Additional pathways that synergize 
with IFNG to promote disease maintenance through 
autoimmune memory in the skin offer further avenues for 
targeted immunotherapy. Patients treated with anti-PD-1 
therapies for melanoma develop vitiligo-like lesions 
consisting of multiple flecked lesions. Significantly, such 
lesions are not associated with the Köbner phenomenon, or 
other autoimmune comorbidities. In contrast, increased 
CXCL10 levels in serum of patients developing vitiligo-like 
lesions are associated with skin infiltration of CD8+ T cells 
expressing C-X-C motif chemokine receptor 3 (CXCR3), 
elevated levels of IFNG, and production of tumor necrosis 
factor alpha (TNFA). The mechanism of phenol-induced 
vitiligo depigmentation involves specifically activated CD8+ 
T cell responses against pigmented cells, and not against 
keratinocytes. 
Perilesional skin biopsies from Sinclair swine 
vitiligo lesions respond to DNA vaccination with a 
melanocyte antigen sufficient to drive autoimmunity and 
provide a unique opportunity to study the process of 
repigmentation in animal-derived skin with human-like 
properties. A new method for studying the cellular and 
molecular foundation of vitiligo was presented by 
combining immunostaining with laser capture 
microdissection to define the number and phenotype of 
melanocyte stem cell populations in the hair follicle bulge 
during narrowband UVB treatment of vitiligo patients 
(Goldstein et al., 2018). This strategy facilitates 
identification of pathways that govern repigmentation in 
human vitiligo. 
Currently, clinical dermatologists have the 
opportunity to build on successes of melanoma research, 
largely through understanding immune checkpoint 
pathways. By building on existing genomic profiles and by 
connecting immunological signatures of melanocyte-
derived samples with patient and context-specific 
questions, dermatological subdisciplines have the potential 
to rapidly translate molecular insights into the clinic. 
2.3.3 Progress in vitiligo genetics 
Genome-wide association studies have 
discovered approximately 50 genetic loci contributing to 
vitiligo risk in European-derived Caucasians. For many of 
these vitiligo susceptibility loci, the relevant causal gene 
and DNA sequence variants have been identified. 
Corresponding genes are involved in immune and apoptotic 
regulation, melanocyte function, and autoimmune 
targeting (Spritz and Andersen, 2017). Study of population 
isolates with a high prevalence of vitiligo (by combining 
association and linkage approaches) provides a unique 
opportunity to ascertain the genetic architecture of vitiligo 
in relatively simple, homogeneous populations. 
In vitiligo research, quantifying and standardizing 
clinical outcome remains a challenge. Accurately 
quantifying vitiligo extent and repigmentation in response 
to treatment by computer-assisted technologies are 
important recent initiatives. Validation of disease extent 
and target lesion repigmentation using automation and 
standardized digital photography will be indispensable for 
this. Patients’ viewpoints are congruently important 
determinants in formulating severity and repigmentation 
scores, as emphasized during the vitiligo working group 
meeting. 
2.4 SECTION 4—BASIC PIGMENT CELL RESEARCH 
2.4.1 Photochemistry and pathophysiology of 
pigments 
Topics in photochemistry and pathophysiology of 
pigments included bioorganic chemistry of eumelanin, 
photobleaching of synthetic pheomelanin, neuromelanin in 
neurodegenerative processes, and the elevated redox 
potential of pheomelanin compared to eumelanin, thus 
accounting for its higher pro-oxidant activity. Density 
functional theory based calculations and the effect of 
functional groups on the rate of cyclization of quinones of 
dopamine, dopa, and N-methyldopamine provide ab initio 
insights in chromophore binding energies, stabilization, and 
dynamics. New directions include the molecular 
understanding of insect cuticular pigmentation. Similar to 
the oxidative polymerization of melanogenic precursors, 
dopamine and cysteinyl dopamine, in insect pigmentation, 
sclerotinogenic precursors—N-acetyldopamine and N-
alanyldopamine—are utilized. 
Chemically-excited electrons take on a key role in 
photoproduct formation after UV irradiation. During UV-
exposure, cyclobutane pyrimidine dimers (CPDs) are 
created by coordinated opening of two double bonds on 
adjacent pyrimidine bases (thymine or cytosine) to join the 
bases in a cyclobutane ring, a reaction possible only after an 
electron has been excited. Extraordinarily high energies 
during UV exposure are accompanied by electron excitation 
and drastically altered orbital shapes, allowing reactions 
that quantum mechanics otherwise forbids. CPDs then lead 
to the UV signature mutations underlying melanoma and 
other skin cancers. Surprisingly, melanocytes were 
discovered to also generate CPDs for hours after UV 
exposure ended. Such dark CPDs constituted the majority 
of CPDs in human melanocytes in vitro and mouse skin, and 
were most prominent in skin containing pheomelanin. The 
mechanism was found to be excitation of an electron by a 
chemical reaction involving melanin, superoxide, and nitric 
oxide, rather than by a photon. Chemiexcitation is familiar 
in fireflies but was unknown in mammals. Evidently, 
melanin is carcinogenic as well as protective. 
Chemiexcitation is therefore a new mode of pathogenesis 
that contributes to the CPD footprint known to result in UV 
signature mutations in melanoma genomes. The process 
may also underlie diseases in tissue never exposed to UV: 
Inflammation generates superoxide and nitric oxide and 
these three factors colocalize with melanin or 
neuromelanin in tissues susceptible to macular 
degeneration, noise-induced deafness, and Parkinson's 
disease. 
Pathophysiological processes involve 
considerable physicochemical changes of melanin and its 
derivatives, affecting biological functions of pigments. 
Melanin granules of the aging human retinal pigment 
epithelium can be impaired by sublethal photic stress, 
leading to phototoxicity. Interestingly, such phototoxic 
effects mediated by the aging pigment granules can be 
reversed by natural antioxidants. Consistent with this idea, 
retinal pigment epithelium melanin from younger donors 
was found to be more photoreactive, showing less 
phototoxicity. Investigations of the redox properties of 
insoluble melanin exemplify how electrochemical detection 
is able to simultaneously record optical and redox-based 
outputs. This enables researchers to trace the generation 
and quenching of radicals that play critical roles as mediator 
molecules to create oxidized or reduced forms of 
chromophores. Thus, electrochemistry provides a unique 
insight into the redox-cycling capabilities of melanin 
impacting the biological redox homeostasis of pigmented 
cells. 
2.4.2 Genetics of pigmentation 
Recent advancements in genomic profiling reveal 
that homologous genes in humans are not only involved in 
pigmentation disease but also determine skin and hair color 
in vertebrates. In addition, the field of pattern formation 
includes the attractive study of how genetic variation 
influences gradients of pigment factors. Comparative 
animal models together with human genetics are utilized to 
study the evolution of pigmentary systems. Work on coat 
pattern formation using the African striped mouse shows 
how dorsal racing stripes are established in rodents, others 
mammals, and fish. Using the Zebrafish as a model system, 
it is possible to study the long-distance influence 
macrophages play in adult pigmentation pattern 
development. 
It is essential to understand the molecular, 
cellular and genetic foundations of these patterns that are 
common across species to help understand the 
evolutionary processes under phenotypic selection. The 
transcription factor ALX homeobox 3 (Alx3) was identified 
as a primary regulator of melanocyte maturation through 
the pattern of expression in the embryo via inhibition of the 
Mitf gene within the melanocyte, thereby suppressing 
pigmentation and giving the appearance of light colored 
hair (Mallarino et al., 2016). Notably, chipmunks have 
independently evolved a similar dorsal light stripe pattern 
through ALX3 regulation of MITF. The contribution of agouti 
signaling protein (Asip) as a differentially expressed gene in 
the patterning process is yet to be fully defined. In human 
populations, where pigmentation is studied as a variable 
trait, most interest has focused on why lighter populations 
arose from darker ancestors upon leaving Africa. Recent 
genomic insights revealed the distribution of skin colors in 
African and human ancestral populations. The architecture 
of skin pigmentation showed unprecedented variation 
across human populations and revealed different 
evolutionary influences. Similar mechanisms, gradients of 
pigmentation, and selection pressures applied to Africans 
and Europeans. Genetic evidence indicated that the light 
pigmentation variant at melanosome solute carrier 
SLC24A5 was introduced into the Eastern African 
population by gene flow from non-Africans (Crawford et al., 
2017; Martin et al., 2017). The rs1426654(L374F) change 
has a big effect on skin type in Europeans. However, it was 
unexpected that this allele seems to have gone back into 
African populations and is also driving lighter skin across 
these populations. Other notable findings are the 
involvement of hitherto unreported genes in pigmentation 
variation. These are Mfsd12, confirmed by testing in animal 
models, that is mouse grizzled coat color, and associated 
with dark skin; Ddb1/Tmem138, increased expression 
suggests increased DNA repair being associated with 
pigmentation responses. The identified SNPs still only 
explain about 30% of the variance seen in understudied 
African pigmentation, so other genes remain to be 
discovered. Currently, the UK Biobank, with more than 
500,000 individuals, provides the widest range of 
pigmentation genotype-phenotype interactions 
characterized so far. 
Human genetic information has potential for 
implementation into the dermatology clinic for the delivery 
of personalized medicine. Difficulties and challenges of 
germline genomic analysis of patients at high risk of 
melanoma have to be carefully taken under consideration. 
Using cultured clonal human melanocytes as a model 
system, the effect of transcription factor interferon 
regulatory factor 4 (IRF4) in pigmentation biology and 
interferon-gamma response is under investigation. 
Congenic cultures with homozygous allele variation in an 
IRF4 intronic regulatory region differed with respect to 
expression of chemokines and immune checkpoints, CCL3, 
CCL5, CTLA4 and PD-L1. 
3. Conclusion 
Shared success and progress of the pigment cell 
research community in understanding of cellular and 
immunological homeostasis of pigment cells but also 
clinical challenges and hurdles in the treatment of 
melanoma and dermatological disorders continue to drive 
future research activities. Investigators in the pigment cell 
research community have diverse but complementary 
backgrounds, and include chemists, physicists, basic 
biological scientists, dermatologists, surgeons, oncologists, 
epidemiologists, bioinformaticians, and biomedical 
engineers. The cross-disciplinary nature of the field is 
unique, unified around a passion for understanding the 
establishment and maintenance of normal pigmentation, 
and benign or malignant pigmentary diseases. This fosters 
the generation of new translational research ideas crossing 
multiple disciplines. 
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